FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4282925006> ?p ?o ?g. }

• W4282925006 endingPage "3784" @default.
• W4282925006 startingPage "3784" @default.
• W4282925006 abstract "Abstract Cellular integrated stress response (ISR) pathways are induced by multiple triggers - viral RNA, nutrient deprivation, protein misfolding and disruption of mitochondrial homeostasis -that lead to phosphorylation of eIF2α, blockade of translation and activation of transcription factor ATF4 allowing the cell to recover or become apoptotic. These pathways are emerging as important targets in oncology, and here we demonstrate that mitochondrial homeostatic pathways can be co-opted to induce apoptosis in tumor cells and complete tumor regression in xenograft and PDX models. Diffuse large B-cell lymphoma (DLBCL) is a highly heterogeneous tumor, for which novel therapies are needed. We recently described BTM-3566, a small molecule which induces apoptosis in DLBCL cell lines, including double- and triple-hit subtypes. In xenograft models BTM-3566 induces complete and durable regression in all tumor-bearing animals, importantly, no regrowth is seen through 21 days post therapy. In an expanded panel of high-risk human DLBCL PDX models BTM-3566 demonstrated a 100% response rate, and complete tumor regression in 6 of 8 PDX models. Molecular analysis revealed that BTM-3566 activates the mitochondrial protease OMA1, leading to activation of HRI kinase, phosphorylation of the eIF2a -ATF4 pathway and apoptosis in DLBCL cell lines. CRISPR-Cas9 depletion of OMA1 eliminates BTM-3566’s apoptotic activity. Substrates of OMA1 include dynamin, OPA1 and DELE1, a protein of unknown function but which has recently been shown to act as a sensor for mitochondrial dysfunction and signals through HRI kinase and ATF4. Transfection of BJAB cells with a cleavage resistant OPA1 mutant has no effect on BTM-3566 induced apoptosis. In contrast, KO of DELE1 suppresses BTM-3566 mediated apoptosis. Interestingly, knockout of the ATF4 gene has a partial effect, delaying onset of apoptosis. BTM-3566 activates OMA1 in a manner unrelated to changes in mitochondrial ATP synthesis, reactive oxygen species generation or electron transport chain inhibition. Instead, BTM-3566 induces OMA1 activity through a novel mechanism regulated by the mitochondrial protein FAM210B. FAM210B expression is negatively correlated with response to BTM-3566, and overexpression of FAM210B blocks OMA1 activation and causes complete resistance to BTM-3566 induced apoptosis. Thus, FAM210B expression is a strong predictor of sensitivity to BTM-3566 and reveals a novel mechanism of regulation of OMA1 activation. Taken together, these data support a novel antitumor mechanism in DLBCL, where BTM3566 induces mitochondrial stress, activating the OMA1-DELE1-HRI-eIF2a-ATF4 pathway leading to apoptosis and tumor regression. An Investigational New Drug application for BTM3566 in B-cell malignancies will be submitted by early Q1 2022 with initiation of first in human clinical trials the first half of 2022. Citation Format: Adrian Schwarzer, Matheus Oliveira, Marc-Jens Kleppa, Andy Anantha, Alan Cooper, Todd Hembrough, Jedd Levine, Michael Luther, Michael Stocum, Marc Liesa-Roig, Matt Kostura. BTM-3655 co-opts mitochondrial quality control pathways to induce apoptosis, and complete tumor regression in DLBCL cell lines, xenografts and PDX models [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2022; 2022 Apr 8-13. Philadelphia (PA): AACR; Cancer Res 2022;82(12_Suppl):Abstract nr 3784." @default.
• W4282925006 created "2022-06-16" @default.
• W4282925006 creator A5028319190 @default.
• W4282925006 creator A5032103167 @default.
• W4282925006 creator A5040956604 @default.
• W4282925006 creator A5045522995 @default.
• W4282925006 creator A5045565087 @default.
• W4282925006 creator A5048369693 @default.
• W4282925006 creator A5051174345 @default.
• W4282925006 creator A5059744648 @default.
• W4282925006 creator A5063442683 @default.
• W4282925006 creator A5064578298 @default.
• W4282925006 creator A5064715897 @default.
• W4282925006 date "2022-06-15" @default.
• W4282925006 modified "2023-10-07" @default.
• W4282925006 title "Abstract 3784: BTM-3655 co-opts mitochondrial quality control pathways to induce apoptosis, and complete tumor regression in DLBCL cell lines, xenografts and PDX models" @default.
• W4282925006 doi "https://doi.org/10.1158/1538-7445.am2022-3784" @default.
• W4282925006 hasPublicationYear "2022" @default.
• W4282925006 type Work @default.
• W4282925006 citedByCount "0" @default.
• W4282925006 crossrefType "journal-article" @default.
• W4282925006 hasAuthorship W4282925006A5028319190 @default.
• W4282925006 hasAuthorship W4282925006A5032103167 @default.
• W4282925006 hasAuthorship W4282925006A5040956604 @default.
• W4282925006 hasAuthorship W4282925006A5045522995 @default.
• W4282925006 hasAuthorship W4282925006A5045565087 @default.
• W4282925006 hasAuthorship W4282925006A5048369693 @default.
• W4282925006 hasAuthorship W4282925006A5051174345 @default.
• W4282925006 hasAuthorship W4282925006A5059744648 @default.
• W4282925006 hasAuthorship W4282925006A5063442683 @default.
• W4282925006 hasAuthorship W4282925006A5064578298 @default.
• W4282925006 hasAuthorship W4282925006A5064715897 @default.
• W4282925006 hasConcept C104317684 @default.
• W4282925006 hasConcept C105580179 @default.
• W4282925006 hasConcept C139447449 @default.
• W4282925006 hasConcept C149364088 @default.
• W4282925006 hasConcept C190283241 @default.
• W4282925006 hasConcept C2779638656 @default.
• W4282925006 hasConcept C2780900454 @default.
• W4282925006 hasConcept C502942594 @default.
• W4282925006 hasConcept C54355233 @default.
• W4282925006 hasConcept C86803240 @default.
• W4282925006 hasConcept C95444343 @default.
• W4282925006 hasConceptScore W4282925006C104317684 @default.
• W4282925006 hasConceptScore W4282925006C105580179 @default.
• W4282925006 hasConceptScore W4282925006C139447449 @default.
• W4282925006 hasConceptScore W4282925006C149364088 @default.
• W4282925006 hasConceptScore W4282925006C190283241 @default.
• W4282925006 hasConceptScore W4282925006C2779638656 @default.
• W4282925006 hasConceptScore W4282925006C2780900454 @default.
• W4282925006 hasConceptScore W4282925006C502942594 @default.
• W4282925006 hasConceptScore W4282925006C54355233 @default.
• W4282925006 hasConceptScore W4282925006C86803240 @default.
• W4282925006 hasConceptScore W4282925006C95444343 @default.
• W4282925006 hasIssue "12_Supplement" @default.
• W4282925006 hasLocation W42829250061 @default.
• W4282925006 hasOpenAccess W4282925006 @default.
• W4282925006 hasPrimaryLocation W42829250061 @default.
• W4282925006 hasRelatedWork W1787542880 @default.
• W4282925006 hasRelatedWork W1974968790 @default.
• W4282925006 hasRelatedWork W2084952088 @default.
• W4282925006 hasRelatedWork W2292160905 @default.
• W4282925006 hasRelatedWork W2514036928 @default.
• W4282925006 hasRelatedWork W2625207659 @default.
• W4282925006 hasRelatedWork W2811512808 @default.
• W4282925006 hasRelatedWork W2961295391 @default.
• W4282925006 hasRelatedWork W4295500741 @default.
• W4282925006 hasRelatedWork W4385968531 @default.
• W4282925006 hasVolume "82" @default.
• W4282925006 isParatext "false" @default.
• W4282925006 isRetracted "false" @default.
• W4282925006 workType "article" @default.